Study:
A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal
Rationale:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Combining more than one drug or combining radiation therapy
with chemotherapy may kill more tumor cells. It is not yet known whether fluorouracil and
mitomycin plus radiation therapy is more effective than fluorouracil and cisplatin plus
radiation therapy for anal cancer.
Purpose:
This randomized phase III trial is studying fluorouracil and mitomycin plus
radiation therapy to see how well it works compared to fluorouracil and cisplatin plus
radiation therapy in treating patients with stage II or stage III anal cancer.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Anal Cancer |
Drug: cisplatin
Drug: fluorouracil
Drug: mitomycin C
Radiation: radiation therapy |
Phase 3 |
Verified by
Radiation Therapy Oncology Group
June, 2005
Sponsored by: Radiation Therapy Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00003596
Study Type: Interventional
Study Design: Allocation: Randomized, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Jaffer A. Ajani, MD., Study Chair
Al B. Benson, MD, FACP., Study Chair
Joel E. Tepper, MD., Study Chair
John S. MacDonald, MD., Study Chair
Michael G. Haddock, MD., Study Chair